Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep MedicineMedical Mutual - Ohio Narcolepsy Prior Auth Policy…
    Ask Trek AI about this page
    CurrentMedical Mutual - OhioPolicy N/A

    Narcolepsy Products Prior Authorization Policy

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements for Wakix, sodium oxybate products (Xyrem, Xywav, Lumryz) for narcolepsy and related indications; applies to pharmacy benefit coverage decisions for members under Medical Mutual - Ohio.

    Policy Summary
    PayerMedical Mutual - Ohio
    PolicyNarcolepsy Products Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeAnnual review (no material changes)
    Effective DateN/A
    Last ReviewMar 19, 2026
    Next Review DateAug 21, 2025
    Key ActionObtain prior authorization and ensure initial prescribing is by or in consultation with a sleep specialist or neurologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4impacted drugs listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3mo / 1yrapproval durations
    ≥6–≥18age range
    Sleep studydiagnostic testing required

    Coverage Criteria for Narcolepsy Products

    Wakix — Excessive Daytime Sleepiness (EDS) with Narcolepsy

    Covered when ALL of the following are met:

    Wakix EDS criteria (alternate serialized): Patient must meet A-E

    Concomitant use of sodium oxybate products is not recommended. Specifically, Lumryz, sodium oxybate oral solution (Xyrem), and Xywav should not be used together or alternated because they contain the same active moiety (oxybate) and have not been studied in combination. Additionally, use of any oxybate product in combination with Wakix (pitolisant) or Sunosi (solriamfetol) is not recommended due to lack of published evidence evaluating such combinations and potential safety concerns related to combining a CNS depressant with other wake-promoting agents.

    Long‑term maintenance treatment of fibromyalgia with sodium oxybate products is not recommended. An FDA advisory panel previously rejected approval of Xyrem for fibromyalgia based on trials that failed to show significant efficacy versus existing fibromyalgia therapies and concerns about limited information on drug interactions; therefore chronic use for this indication lacks supporting evidence.

    Coverage is not recommended for uses or situations that are not explicitly listed in the Recommended Authorization Criteria. The policy will be updated if new published data support additional indications, but until then requests outside the specified criteria should be denied as not meeting medical necessity.

    Wakix, sodium oxybate oral solution (Xyrem), Lumryz, and Xywav are not recommended for certain conditions because evidence is insufficient or safety concerns exist. Examples include long‑term maintenance therapy for fibromyalgia (Xyrem, Lumryz, Xywav) and other unlisted indications where clinical benefit has not been established. The policy notes that these products have limited or preliminary data for such conditions and that the list of non‑recommended conditions is not exhaustive.

    Impacted Drugs, Age Criteria, and Codes

    Impacted drugsNDC
    Wakixpitolisant tablets
    Xyremsodium oxybate oral solution
    Xywavcalcium, magnesium, potassium, and sodium oxybates oral solution
    Lumryzsodium oxybate extended-release oral suspension
    Impacted drugs (alternate listing)mixed
    Wakixpitolisant tablets - Harmony
    Xyremsodium oxybate oral solution - Jazz, generic
    Xywavcalcium, magnesium, potassium, and sodium oxybates oral solution - Jazz
    Lumryzsodium oxybate extended-release oral suspension - Avadel
    Minimum age by product/indication
    Wakix (pitolisant)>= 6 years for EDS and cataplexy (per Wakix criteria)
    Lumryz (sodium oxybate ER)>= 7 years for narcolepsy indications (EDS and cataplexy)
    Xyrem (sodium oxybate oral solution)>= 7 years for narcolepsy indications (EDS and cataplexy)
    Xywav (calcium/magnesium/potassium/sodium oxybates)>= 7 years for narcolepsy indications; >= 18 years for idiopathic hypersomnia

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the listed narcolepsy products prior to pharmacy benefit coverage. Initial approvals require the drug be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted in the policy; reauthorization requires documented response to therapy when continuation is allowed.

    • Affected products: Wakix (pitolisant), Xyrem (sodium oxybate), Xywav (mixed-cation oxybate), Lumryz (sodium oxybate ER).
    • Prescriber requirement: prescribed by or in consultation with a sleep disorder specialist, neurologist, pulmonologist, or psychiatrist as specified per criteria.
    Step Therapy

    Step-Therapy / Multiple-Step Requirements

    Step-therapy and multiple-step requirements apply and vary by product and indication. For EDS and cataplexy criteria, trials of modafinil or armodafinil, or trials of CNS stimulants (e.g., methylphenidate, dexmethylphenidate, dextroamphetamine) are required per the specific product/age/indication rules. For some adult EDS criteria additional prior trials may include Lumryz, Sunosi, and Wakix or documented contraindications/intolerance to those agents.

    Background and Clinical Context

    Wakix (pitolisant) is a non‑controlled histamine‑3 (H3) receptor antagonist/inverse agonist indicated for treatment of excessive daytime sleepiness (EDS) and for reduction of cataplexy in narcolepsy. Sodium oxybate products (Xyrem, Xywav, Lumryz) are formulations of oxybate, a CNS depressant indicated for EDS and cataplexy in narcolepsy (age thresholds vary by product), and Xywav additionally has an indication for idiopathic hypersomnia in adults. Diagnosis confirmation for these disorders commonly requires polysomnography and multiple sleep latency testing, and prior authorization is required for these agents with initiation by or in consultation with a sleep specialist or neurologist per the policy.

    Key Definitions

    EDS (Excessive Daytime Sleepiness) — definition and covered products
    DefinitionExcessive daytime sleepiness (EDS) associated with narcolepsy: daytime sleepiness in patients with narcolepsy confirmed by polysomnography and multiple sleep latency testing (MSLT); covered products include wakefulness‑promoting agents (e.g., Wakix) and sodium oxybate preparations for treatment as specified by age and prior therapy.
    Required diagnostic evaluationPolysomnography and multiple sleep latency test (MSLT) are required to confirm narcolepsy/EDS in covered criteria.
    Covered product classesNon‑controlled wakefulness‑promoting agent (pitolisant/Wakix) and sodium oxybate products (Xyrem, Xywav, Lumryz).
    Prescribing requirementMedication must be prescribed by or in consultation with a sleep disorder specialist, neurologist, pulmonologist, or psychiatrist as specified in product criteria.
    Wakix (pitolisant) — description and indications

    Revision History

    2026-03-19policy_revisionLatest

    Policy last revised; document lists Last Revised Date as 03/19/2026.

    2025-08-21next_review

    Annual review date / next scheduled review is 08/21/2025 as listed in the policy header.

    2024-06-24reference_update
    Policy Summary
    PayerMedical Mutual - Ohio
    PolicyNarcolepsy Products Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeAnnual review (no material changes)
    Effective DateN/A
    Last ReviewMar 19, 2026
    Next Review DateAug 21, 2025
    Key ActionObtain prior authorization and ensure initial prescribing is by or in consultation with a sleep specialist or neurologist.
    SourceLink
    On This Page
    Coverage Criteria for Narcolepsy ProductsImpacted Drugs, Age Criteria, and CodesProvider Actions, Prior Authorization, and DocumentationBackground and Clinical ContextKey DefinitionsRevision History
    • Examples: adults may need trials of two agents from CNS stimulant/modafinil/armodafinil; pediatric criteria may require one trial depending on age and indication.
    • For idiopathic hypersomnia (Xywav) the patient must have tried at least one of modafinil, armodafinil, or methylphenidate.
    Documentation Required

    Documentation May Be Requested

    The Company may request additional documentation to support medical necessity as part of its coverage determination.

    • Documentation may include patient medical records, polysomnography and multiple sleep latency test (MSLT) results, and provider credentials.
    • Be prepared to supply requested records promptly to avoid delays or adverse coverage determinations.
    Denial Risk

    Denial Risk for Insufficient Criteria or Documentation

    The Company may deny reimbursement when coverage criteria are not met or documentation is insufficient.

    • Denial reasons include: drug or service not medically necessary, investigational or experimental, not within the member's benefits, or inappropriate/excessive billing patterns.
    • Ensure submitted documentation demonstrates medical necessity and meets the policy's diagnostic and prior-trial requirements to reduce denial risk.
    Drug descriptionWakix (pitolisant) — an antagonist/inverse agonist of the histamine‑3 (H3) receptor; the only wakefulness‑promoting agent in this policy that is not a controlled substance.
    IndicationsIndicated for excessive daytime sleepiness (EDS) in adults and pediatric patients >= 6 years with narcolepsy; indicated for cataplexy in adults with narcolepsy.
    Prescribing contextUse covered when prescribed by or in consultation with a sleep specialist physician or neurologist and when diagnostic criteria (polysomnography/MSLT and confirmed narcolepsy) are met.

    References accessed/updated (e.g., NIH narcolepsy page and AASM guidance) on June 24, 2024 per reference citations.